HuGE Literature Finder
Records
1
-
12
| Pharmacokinetics of a Once Daily Tacrolimus Formulation in First Nations and Caucasian Liver Transplant Recipients. Transplant international : official journal of the European Society for Organ Transplantation 2021 Jul . Peretz David, On Ngoc H, Miller Donald, Kim Richard, Franklin Carla, Dascal Roman, Knowles Cori, Minuk Gerald |
| Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. Scientific reports 2021 Jan 11 (1): 443. Pinon Michele, De Nicolò Amedeo, Pizzol Antonio, Antonucci Miriam, D'Avolio Antonio, Serpe Loredana, Dell'Olio Dominic, Catalano Silvia, Tandoi Francesco, Romagnoli Renato, Canaparo Roberto, Calvo Pier Lui |
| Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. European journal of clinical pharmacology 2020 Aug . Wang Junyan, Huang Lingfei, Gao Peng, Hu Yan, Ni Yinghua, Zhu Zhengyi, Zhang Liwen, Yang Jufei, Zhang Huifen, Fang L |
| Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients. British journal of clinical pharmacology 2019 May . Anutrakulchai Sirirat, Pongskul Cholatip, Kritmetapak Kittrawee, Limwattananon Chulaporn, Vannaprasaht Su |
| The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients. Archives of medical science : AMS 2018 Oct 14 (6): 1416-1423. Belohlavkova Petra, Vrbacky Filip, Voglova Jaroslava, Racil Zdenek, Zackova Daniela, Hrochova Katerina, Malakova Jana, Mayer Jiri, Zak Pav |
| CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment. Pharmacogenomics and personalized medicine 2018 11 23-33. Chen Lucy, Prasad G V Rame |
| Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients. Pharmacogenetics and genomics 2014 Dec 24 (12): 597-606. Kuypers Dirk R J, de Loor Henriette, Naesens Maarten, Coopmans Tamara, de Jonge Hyl |
| Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. Journal of gastroenterology and hepatology 2014 Jan 29 (1): 60-6. Hirai Fumihito, Takatsu Noritaka, Yano Yutaka, Satou Yuhou, Takahashi Haruhiko, Ishikawa Satoshi, Tsurumi Kozue, Hisabe Takashi, Matsui Toshiyu |
| CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast cancer research and treatment 2012 Jul 134 (1): 401-10. Hertz Daniel L, Motsinger-Reif Alison A, Drobish Amy, Winham Stacey J, McLeod Howard L, Carey Lisa A, Dees E Clai |
| CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation 2010 Dec 90 (12): 1394-400. Min Sang-Il, Kim Seong Yup, Ahn Sang Hyun, Min Seung-Kee, Kim Si Hwa, Kim Yon Su, Moon Kyung Chul, Oh Jung Mi, Kim Sang Joon, Ha Jongw |
| Optimization of initial tacrolimus dose using pharmacogenetic testing. Clinical pharmacology and therapeutics 2010 Jun 87 (6): 721-6. Thervet E, Loriot M A, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng A E, Subra J F, Beaune P, Legendre |
| Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis and rheumatism 2004 Jul 50 (7): 2202-10. Takada Kazuki, Arefayene Million, Desta Zeruesenay, Yarboro Cheryl H, Boumpas Dimitrios T, Balow James E, Flockhart David A, Illei Gabor |
- Page last reviewed:Oct 1, 2021
- Page last updated:Oct 20, 2021
- Content source: